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ABSTRACT 
Objective: This study aims to develop and validate the analytical method to determine 3,4-Methylenedioxy-N-ethylamphetamine (MDEA) in DBS 
using GC-MS.  
Methods: This research used liquid-liquid micro-extraction for sample preparation and analysis was performed by GC-MS. In the method develop-
ment, the optimized parameters were flow rate, column temperature, the spot of blood volume, % haematocrit, extraction and reconstitution of 
solvent volume, and sonication duration. Validation of the chosen method was performed based on EMEA bioanalytical guideline in 2011.  
Results: The optimum chromatographic conditions were obtained using HP-5 MS capillary columns (30 m x 0.25 mm i.d; 0.25 μm ); helium with 
99.9% purity as a mobile phase; flow rate of 1.0 ml/min; column temperature was 250 °C; MS detection using 4 fragments at m/z values of 72.00 
and 44.00 for MDEA and 58.00 and 77.00 for ephedrine HCl as an internal standard. The DBS paper with the volume of blood spot 40 μl was then 
extracted using liquid-liquid micro-extraction with methanol 700 μl, sonication for 5 min, evaporated with nitrogen gas then reconstituted with 50 
μl ethyl acetate. The validation results fulfilled the requirements based on the EMEA bioanalytical guideline in 2011.  
Conclusion: It can be concluded that the optimum condition of the analytical method by using GC-MS was obtained and fulfilled validation criteria 
with a range concentration of 15-250 ng/ml. 
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INTRODUCTION 
Drug abuse has been increasing in recent years. Based on World Drug 
Report on 2017, it is said that the prevalence of drug abuse is 4.8% in 
2009, increased to 5.2% by 2011, and to 5.3% by 2015 [1]. One of the 
abused substances was amphetamine type-stimulant (ATS), such as 
3,4-Methylenedioxy-N-ethylamphetamine (MDEA) [2]. Amphetamine 
is part of the psychotropic groups as one of the Narcotics, 
Psychotropic, and Addictive Substances. According to Indonesia Law 
No. 5 y 1997, psychotropic substances or drugs are either natural or 
synthetic that can lead to psychoactive efficacy in the form of selective 
influence on the central nervous system that causes a distinctive 
change in mental activity and behavior. Psychotropic can be classified 
into four groups: Group I, Group II, Class III, and Group IV. However, 
since the enactment of Indonesia Law no. 35 y 2009, psychotropic 
class I and class II have been classified as narcotics [3]. 
MDEA belongs to class I drug according to the regulation [3]. This 
compound is an entactogen and belongs to the amaphetamine in 
Indonesia type and the class of phenylethylamine [4]. To declare status 
of a person is positive using drugs, it must be proven through the 
identification of the abused compounds in biological matrices such as 
blood, urine, hair, and saliva. There are some drawbacks to the use of the 
matrix. In the urine sample, it is susceptible to counterfeiting and 
sometimes is considered as a privacy violation. In the hair samples, the 
deficiencies are expensive and the use of recently used drugs cannot be 
detected. In saliva samples, the deficiency is in the form of drug 
availability is only slightly in time compared to urine [5]. In the narcotic 
drug analysis, tests performed using the new method, dried blood spots 
(DBS) are still few in numbers. Thus, it is necessary to do research using 
DBS [6]. This DBS method uses filter paper and blood samples. The 
advantage of this method, is that it only needs small volume of blood, not 
invasive to the body, stable sample, and easy to handle [7]. 
The first step of analysis is sample preparations, namely protein 
precipitation method, solid-phase extraction and liquid-liquid 
extraction. Based on existing methods, there are some shortfall. 
Protein precipitation methods can produce large amounts of 
impurities. The solid phase extraction method requires a longer step 
than liquid-liquid extraction process and can sometimes cause 
irreversible adsorption of a number of analyte on the used catridge 
[8]. Liquid-liquid extraction has a deficiency in terms of solvent 
toxicity [9] and large amounts of solvents with high polarity and 
often emulsions [10]. One of the recent developed sample 
preparation method is micro-extraction by simplifying sample 
preparation procedures and improving the quality and sensitivity of 
the analysis [11, 12]. In addition, the advantages are fewer solvents 
and less time needed7. The technique can be applied to the analysis 
of drug abuse on a small sample with short analysis time. 
For analysis, there are two instruments that are commonly used, 
Liquid Chromatography (LC) and Gas Chromatography (GC), both 
with mass spectrometry (MS). GC-MS provided some advantages 
such as lower cost and the analysis process can be faster. GC-MS can 
be used to especially analyze compounds that are volatile and heat-
resistant [13]. Therefore, this study aimed to develop and validate 
MDEA analytical method in DBS using GC-MS. Hopefully, a method of 
MDEA analysis in DBS that is validate can be developed, thus can be 
widely applied. 
MATERIALS AND METHODS 
Materials– 
The instruments used in this study were Gas Chromatography-Mass 
Spectrometry (Shimadzu GC-MS QP2010 Ultra), equipped with HP-5 
MS Capillary Column (30 m x 0.25 mm; 0.25 μm ), a syringe 
(Shimadzu), Helium Gas with purity 99,99%, DBS paper (Perkin 
Elmer), micropipette (soccrex acura) and tip, vial GC (Agilent), glass 
tobe inserted on GC vial (Agilent), sonicator, and other glass tools 
such as beaker glass and tube (Iwaki), MDEA 1000 ppm in liquid 
form, 1 ml ampoule (Cerilliant), Ephedrine HCl (BPFI) as internal 
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standard, Methanol (Merck), HCl (Merck), Ethyl Acetate (Merck) and 
Blood (Indonesian Red Cross). 
Method validation results have been conducted in the form of LLOQ 
measurements, linearity calibration curve, selectivity, accuracy, 
precision, carryover, matrix effect, and stability. All parameters met 
the requirements based on EMEA bioanalytical guidelines in 2011. 
In this research, optimization was conducted on some variables such 
as flow rate, column oven temperature of GC-MS, amount of MS 
fragments, blood spot volume, % hematocrit, extraction and 
reconstitution solvent volume, and sonication duration. When 
optimized flow rate, column temperature, and amount of MS 
fragments, MDEA standard solution and Ephedrine HCl 1 ppm (1000 
ng/ml) was injected into GC-MS. The variation used for flow rate 
optimization were 0.8; 1.0; 1.2 ml/min with column temperature set 
into 250 °C at 10 °C/min. The results were compared and the chosen 
condition was assessed based on peak retention time and size of the 
analytical area. The same thing was done when optimized column 
temperature by using the chosen flow rate from the previous 
optimization. Variation are 250; 280; 300 °C, each at 10 °C/min. MS 
optimization was performed by first comparing full scan mode at 
range m/z 50-550 and selected ion monitoring (SIM) mode. After 
that, optimization was continued by a varying number of fragments. 
The chosen fragments were based on the high relative intensity of 
the peak. The chosen fragments for optimization were 4 fragment 
consisting of 2 MDEA fragments (m/z 72 and m/z 44) and 2 
Ephedrine HCl fragments (m/z 58 and m/z 77), 3 fragments are 
consisting of 1 MDEA fragment (m/z 72) and 2 Ephedrine HCl 
fragments (m/z 58 and m/z 77), and 2 fragments consisting of 1 
MDEA fragment (m/z 72) and 1 Ephedrine HCl fragment (m/z 58). 
 
 
Fig. 1: Fragments of mass spectrum of MDEA 
 
Afterward a system suitability test was performed using MDEA and 
Ephedrine standard solution at concentration 1000 ng/ml injected 1 
μl into GC-MS by using selected flow rate, selected number of 
fragments, and selected column temperature. The injection is done 
five replicas, then observe coefficient of variation to the ratio of peak 
area as well as the retention time of analite and internal standard. 
In the optimization of DBS sample preparation was done by 
optimizing the volume of the blood spot, hematocrit, the volume of 
the reconstitution solution, the volume of the extracting solution, 
and the time of sonication. When optimized, the volume of blood 
spot spiked blood sample with a final concentration of 100 ng/ml of 
10, 20, 30, and 40 μl on Perkin Elmer DBS Paper. Then the drying 
and extraction process was performed by cutting the blood spot on 
the paper and adding 500 μl methanol and 100 μl internal standard 
(1000 ng/ml). Afterward, it was sonicated for 15 min using a 
sonicator. Then prepared a vial containing 10 μl of 0.25% HCl 
solution in methanol and transferred the extraction results into the 
vial, dried using nitrogen gas, and reconstituted using 100 μl of ethyl 
acetate solution and transferring the liquid into a glass insert. After 
that, 1 μl of the liquid was injected into gas chromatography-mass 
spectrometry. The selected one will be based on the size of area. In 
the optimization of % hematocrit, there are 6 variations of 
hematocrit used, which were 33, 36, 38 40, 43, and 47%. In this 
optimization process, spike the blood sample as the selected spot 
volume of the previous optimization result with the final 
concentration of 100 ng/ml and the same extraction preparation like 
before was performed. The parameter needed to be observed in this 
optimization was the analyte area. The optimization of the volume of 
the reconstitution solution was carried out by the same extraction as 
the variations of the 50 and 100 μl reconstitution volumes by using 
the selected spot volume and % hematocrit from previous 
optimization results. On the optimization process, the volume of 
extracting solution was carried out by variation of extracting 
solution in the form of 300, 500, and 700 μl methanol using the 
selected reconstitution volume optimization result. The optimization 
of sonication duration was carried out with variations of 5, 15, and 
30 min using the volume of reconstitution and extraction solvent 
from selected optimization results previously conducted. 
After obtaining gas chromatography-mass spectrometry conditions and 
optimization, the results of DBS preparation were validated according to 
EMEA bioanalytical guidelines in 2011. Validation parameters 
performed were the lower limit of quantification measurement (LLOQ), 
calibration curve, accuracy, precision, selectivity, carry over matrix effect, 
and stability of the stock solution and DBS samples [14]. 
RESULTS AND DISCUSSION 
The analysis was carried out using GC-MS equipped with HP-5 MS 
Capillary Column (30 m x 0.25 mm; 0.25 μm ), a syringe (Shimadzu), 
Helium Gas with purity 99,99%. 
Selection of IS 
The chosen internal standard must be similar in physicochemical 
properties with the standard compound. Ephedrine HCl was chosen 
as an internal standard because it has similar physicochemical 
properties with MDEA also, both can be separated by using GC-MS. 
The existence of an internal standard has the function to control the 
error that may occur in analysis, especially when using a very small 
concentration in the biological matrix. 
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Optimization of flow rate and column temperature 
Three types of flow rates used were 0.8; 1.0; and 1.2 ml/min. The 
chosen flow rate and column temperatures are 1.0 ml/min and 250 
°C because it has the highest area. The higher flow rate will make 
retention time become shorter. If the flow rate is lower, it will 
possibly make the separation is not going well. If the flow rate is too 
high, it will possibly make column pressure higher, which also can 
damage the column. 
Optimization of the amount of fragments 
Analysis of MDEA and ephedrine HCl was done using positive 
ionization because the compounds have basic properties. The 
ionization parameters are the temperature of ion source 200 °C, 
interface temperature 250 °C, and solvent cut time of 1.5 min. Based 
on the area, the optimum condition was acquired by using SIM mode 
with four (4) fragments consist of 2 fragments of MDEA and 2 
fragments of Ephedrine HCl were chosen to use in this study. 
 
 
Fig. 2: Mass spectrometry detection of MDEA on SIM mode 
 
Table 1: System suitability test using GC-MS 
No. Area (µV/s) Retention time (min) PAR 
MDEA Ephedrine HCl MDEA Ephedrine HCl  
1 277319 149604 10.745 8.132 1.85 
2 282774 152109 10.743 8.123 1.86 
3 278393 148730 10.745 8.130 1.87 
4 283773 148283 10.746 8.131 1.91 
5 277196 152175 10.743 8.132 1.82 
mean±SD 279891±3142.60 150180±1852.97 10.744±1.34 8.130±3.78 1.86±0.03 
CV (%) 1.12 1.23 0.01 0.05 1.79 
  
System suitability test 
This test was performed by injecting standard solution 5 times. The 
result was the percentage of coefficient variance (CV) below 2%. 
Thus, it met the requirement. 
Optimization of blood spot volume and % haematocrit 
After doing the system suitability test, GC-MS optimum condition has 
been obtained, which can be used to analyse MDEA in DBS sample. In 
DBS, various optimizations are performed to achieve the best possible 
conditions. The preparation was done without derivatization. 
In this optimization, various amount of blood spot volume and % 
hematocrit were used. The amount of blood spot volume may affect 
the drawing capacity of the MDEA compound from the liquid-liquid 
extraction process carried out in this study. For hematocrit, the 
higher the hematocrit, the higher also the viscosity of blood. The 40 
μl spot volume and 43% hematocrit has the largest area. Thus, it is 
the most optimal spot volume and % hematocrit to be used in this 
study. From these results, it can also be said that with a 40 μl spot 
volume, MDEA compound withdrawal capacity is better than that of 
other bottling volumes. The volume 50 μl was not used because the 
bottle exceeds the circle limit for the blood spot on the paper. 
Optimization of reconstitution and extraction of solvent volume 
From the result, the optimal reconstitution volume used is 50 μl 
viewing the resulting area larger than the 100 μl. This is due to the 
more concentrated 50 μl that can affect the detection process on the 
tool so that the analytical readings get better. For extraction solvent 
volume, 700 μl is the most optimum extraction solvent volume to be 
used in this extraction. It can be seen from the resulting area is 
larger than the other variations of volume. From this point, it can be 
said that with a volume of 700 μl the MDEA compound withdrawal 
capacity from DBS becomes larger. 
Optimization of sonication duration 
Based on the result, 5 min was chosen for sonication time based on 
consideration of the area obtained when compared with the time of 
sonication for 15 min and 30 min, which has different insignificancy 
and efficiency of time required for extraction. 
Below is the chromatogram of the final chosen optimization method
 
 
Fig. 3: Chromatogram of selected method optimization at a concentration of 100 ng/ml (700 μl extraction volume, 5 min sonication, 50 μl 
reconstitution volume)
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LLOQ measurement 
In LLOQ, the measurement was done in 5 replicates, LLOQ 
concentration of 15 ng/ml was obtained with % diff-17.21 to 1.41% 
and CV at 8.63%. From this result, it can be said that the 
measurement of LLOQ meets the criteria that is ≤ ±20%. After that, 
the concentration measurements were taken by half to 7.5 ng/ml. 
From the measurement result, the % diff and CV values obtained do 
not meet the requirements; thus the final LLOQ value was 15 ng/ml. 
The obtained LLOQ value of 15 ng/ml also meets the requirements 
because it still not exceed 5% maximal concentration (Cmax) of 
MDEA in the blood, which is 330 ng/ml [15].  
In the fig. 2 the chromatogram of MDEA at LLOQ concentration is shown. 
 
 
Fig. 4: Chromatogram of MDEA at LLOQ concentration and Ephedrine HCl as IS 
 
Linearity calibration curve  
The obtained linearity also meets the requirements with r ≥0,98 
with a concentration range from 15-250 ng/ml. The calibration 
curve was made consisting of blank samples (DBS without analyte 
and internal standard), zero samples (DBS with internal standard), 
and nonzero samples (DBS with an analyte and internal standard) of 
15, 50, 75, 100, 150, 200, and 250 ng/ml. The analysis was 
performed by observed the linearity, % diff ≤ ±20% for LLOQ, and 
≤±15% for concentrations other than LLOQ.  
The result of the data obtained meets the requirements with % diff 
and CV obtained ≤±20% for LLOQ and ≤ ±15% concentrations other 
than LLOQ. The calibration curve yields a linear regression equation 
y =-0.0046+0.0020x with r = 0.9963 where x is the MDEA (ng/ml) 
concentration and y is the peak area ratio (PAR) between MDEA and 
internal standard. 
The calibration curve was made every day when doing analysis. The 
purpose is to prevent the occurrence of measurement errors due to 
if the GC-MS condition changes between days. The calibration curve 
should meet the ≤ ±20% precision criteria for LLOQ and ≤ ±15% for 
other concentrations. From the measurement of the calibration 
curve between days, the value of CV meets the requirements and the 
correlation coefficient (r) averages 0.9954. 
 





15.00 50.00 75.00 100.00 150.00 200.00 250.00 R Slope Intercep
t 
Number Measured value (ng/ml)    
1 0.00 15.57 55.03 70.03 103.95 132.12 199.11 260.31 0.9954 0.0017 -0.0065 
2 0.00 14.09 45.78 78.25 93.81 164.14 188.74 252.92 0.9963 0.0020 -0.0046 

















0.9954 0.0020 -0.0096 
 
Limit of detection (LOD) 
In the Limit of Detection (LOD) measurements performed on the statistic 
by using calibration curve statistics, it was found to be 8.49 ng/ml. 
Accuracy precision and % recovery 
Accuracy precision was done in 5 replicates from each four 
concentrations (LLOQ, QCL, QCM, and QCH) 3 times at a minimum 2 d. 
Intra-day accuracy testing results were % diff range from-2.12 
to+17.29% for LLOQ and % diff concentrations range from-4.63 
to+14.33% for QC concentrations. For precision, testing results were 
%CV 8.86% for LLOQ and range from 4.85 to 8.53% for QC. The results 
of the accuracy testing results were %diff range from-19.87 to 18.18% 
for LLOQ and % diff range from 14.19 to 14.33% for QC concentrations. 
For precision, testing results were %CV 14.16% and range from 7.74 to 
9.25% for QC. Recovery ot the method was 81.26 to 90.95%. 
 
 
Fig. 5: Chromatogram comparison between sample in LLOQ concentration and blank sample 
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Selectivity 
In this parameter, it was performed using DBS samples of MDEA in 
LLOQ concentrations and DBS blank samples using six different blood 
sources. Selectivity parameter test aims to see if at the retention time 
of MDEA and standard in the presence of interference from blood 
extract in the form of % interference. The requirement is % 
interference ≤ 20% for LLOQ and ≤ 5% for IS. Based on the result, % 
interference were 6.06-9.48% for MDEA and 0.32-0.69% for 
ephedrine HCl. From this result, the method has met the validation 
requirement. 
Matrix effect 
Matrix effect is needed to be tested since the mass spectrometry was 
used for analysis. In this parameter, testing was performed by 
preparing 40 μl blood blot prepared and do the sample preparation. 
The supernatant obtained added MDEA at low concentrations (QCL) 
at 45 ng/ml and high concentrations (QCH) at 187.5 ng/ml. A final 
solution of 1 μl is injected into GC-MS under selected analysis 
conditions. After that, MDEA standard solutions are prepared at low 
concentrations (QCL) and high concentrations (QCH). Thereafter, a 
final solution of 1 μl was injected into GC-MS under selected 
analytical conditions. The above procedure was also done for 
internal standards. The matrix effect was seen by observing the 
matrix factor, i.e. comparing the peak area of MDEA and the internal 
standard in the blood and the peak area of MDEA and the internal 
standard solution. The requirement was %CV ≤15% for QCL and 
QCH. The result testing was the standardized, normalized matrix 
factor in 0.77 for QCL and 0.83 for QCH concentration was obtained. 
Ion suppression was found when seeing the result of the test. This 
can be due to the matrices in the sample affecting the ionization 
process on mass spectrometry. % CV for QCL is 9.35% and 8.16% for 
QCH. Based on the result, the method still met the requirement.  
Carryover 
In this parameter, the test was performed using an MDEA with ULOQ 
concentration (250 ng/ml) and DBS blank sample. This test was 
conducted to observe the interference of MDEA and IS or carryover 
of the previous sample in the blank after the injection of high 
concentrations. DBS blank sample injections were performed after 
the injection of ULOQ concentrations. This test used five replicates 
each and analyzed sequentially. The requirements were % 
interference ≤20% for MDEA and ≤5% for IS. Result of carry over 
test obtained by % interference, which is 7.19% for MDEA at LLOQ 
concentration and 0.47% for ephedrine HCl. 
Stability 
Three types of stability test were done, stock solution at short and long 
term, DBS at short and long term, and autosampler at 0 h and 24 h. 
Stock solution stability 
The result of the stability test of MDEA and Ephedrine HCl stock 
solution can be said that % diff meets the requirement, which was 
below ≤6%. % diff for MDEA in the short term in room temperature 
range from-0.21% to-0.61% and ephedrine HCl in short term range 
from-0.09 % to 0.11%. From this result, it can be said that MDEA 
stock solution and stock solution of Ephedrine HCl remain stable 
during storage in room temperature for 24 h. 
In the long-term stability test results, on day 30, MDEA stock solutions 
had %diff of-0.65% to-1.25% and ephedrine HCl stock solution having 
%diff range from-0.14% to-0.21%. From the result, it can be said that 
MDEA stock solutions and stock solutions of ephedrine HCl remain 
stable during long-term storage for 30 d at 4 °C.  
DBS sample stability 
This parameter is conducted by storing QCL and QCH samples at 
room temperature for 24 h and then observing the stability of the 
hours 0, 6, and 24 by observing % diff. The storage was carried out 
in a sealable plastic equipped with a desiccant. From the results 
obtained it can be said that the short term stability of MDEA in DBS 
meets the requirements of-7.97% to+8.81% for QCL samples and 
2.30% to-9.67% for QCH samples. This indicates that MDEA samples 
within the DBS can be stored at room temperature for 24 h. 
In long-term stability, samples were stored in sealable plastic 
equipped with a desiccant at temperature 4 °C up until 21 d. % diff 
was observed by analyze at day 0 and day 21. From the results 
obtained it can be said that the long-term stability parameters of 
MDEA in DBS meet the requirements with % diff-2.21% to 8.60% for 
QCL samples and-9.64% to 10.80% for QCH samples. From the 
results, it can be said that MDEA samples in DBS can still be stored in 
4°C for 21 d because long-term stability still meets the requirements. 
This is also correlated with research conducted by Ambach et al. in 
2013 that the DBS sample is stable for at least 2 w of storage at 4 °C. 
The results of this stability test also become the advantages of using 
DBS samples that can be stored in the long term before the analysis 
is done [16]. 
Autosampler stability 
The purpose of this test is to know the length of time to store 
samples in the autosampler until it can still be used for the analysis 
process after the extraction process is done. This test is performed 
by injecting QCL and QCH samples at 0 and 24 h. From the test 
result, it can be said that the autosampler stability test parameters 
meet the requirements with% diff ranges from-5.10% to 1.52% for 
QCL and ranges from-10.69% to 11.34% for QCH. From the results, it 
can be said that MDEA samples within the DBS can be stored in the 
autosampler for 24 h before being injected into the tool. 
Based on the result, it could be said that all stability test has fulfilled 
the criteria of validation. 
Based on the results obtained, it can be said that the analytical 
method developed in this study has several advantages. The 
advantages are relatively faster preparation time that is by using 
sonication for 5 min compared to research conducted by Ambach et 
al., which in 2013, using vortex for 15 min [16]. The use of 
sonication may increase the solubility of the analyte to the extracting 
solution when the extraction process is carried out. In addition, 
sonication can also provide a higher recovery [17]. Another 
advantage possessed is when compared with research by Westphal, 
et al. in 2007 on the development of MDEA analysis method in serum 
using GC-MS after derivatization was LLOQ obtained in the current 
study that is 15 ng/ml not so much different from LLOQ in previous 
research that is 13.2 ng/ml [18]. In addition, in this study did not use 
derivatization compared with previous researches [19]. Research on 
MDEA with analysis using GC-MS is not widely practiced especially 
in narcotic analysis. This can be an advantage in this study 
considering that the instrument used is GC-MS and able to detect the 
compound up to a very small concentration [5].  
The next advantage is the process of derivatization was not required. 
In the analysis using GC-MS usually use the derivatization process. 
Derivatization has a number of drawbacks that make longer 
procedural preparation steps and more costly, the data acquisition 
process becomes more complex and longer because derivatization 
can sometimes lead to impurities, the uncertainty of conversion of 
compounds into derivatives, the use of toxic reagents [19, 20]. The 
next advantage is that the preparation of the instrument is relatively 
easier for GC-MS than LC-MS/MS from the aspect of the mobile 
phase. GC-MS uses gas phase while in LC-MS/MS, mobile phase used 
in the form of reagent or reagent mixture so it takes more time to 
prepare before doing analysis. In addition, the operational cost of 
the instrument can be cheaper for GC-MS than LC-MS/MS because in 
GC-MS, mass spectrometry analyzer used in the form of single 
quadrupole while in LC-MS/MS, using triple quadrupole which 
certainly cost more. 
CONCLUSION 
Based on the results, it could be concluded that the optimum condi-
tion of the analytical method by using GC-MS was obtained and has 
fulfilled validation criteria. The developed method was simple with 
liquid-liquid microextraction and without derivatization and was 
linear in range concentration of 15-250 ng/ml. 
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